AstraZeneca secures FDA approval for Lumoxiti in hairy cell leukemia treatment

AstraZeneca has achieved a major regulatory milestone with the US Food and Drug Administration (FDA) approval of Lumoxiti (moxetumomab pasudotox-tdfk), a CD22-directed cytotoxin for the ... Read More